A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes

NCT02119819 · Completed

Last updated 2026-05-28

This clinical trial is testing a new drug for adults with type 2 diabetes by comparing it to a placebo and an existing treatment to see how it affects blood sugar levels over 12 weeks.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 420 people

Who can join Ages 18–80 · all sexes

Timeline Started 2014-04 · est. completion 2015-10

Where 51 sites · Greece, Mexico, Poland, Puerto Rico, Romania, United States

What this study is testing ClinicalTrials.gov NCT02119819 ↗

Description as written by the study sponsor.

The main purpose of this study is to compare the safety and effectiveness of the study drug known as LY2944876 to exenatide extended-release and placebo in participants with type 2 diabetes mellitus. All drugs will be given by an injection under the skin. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry. Participants' involvement in the study is expected to last about 30 weeks.

Treatments tested

LY2944876 Drug

Administered SC
Exenatide extended-release Drug

Administered SC
Placebo Drug

Administered SC
Metformin Drug

Oral

Main thing measured	Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12
Sponsor	OPKO Health, Inc.
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02119819 ↗